| Autor: |
Qiushi, Liang, Fabio, Catalano, Eva C, Vlaar, Joon M, Pijnenburg, Merel, Stok, Yvette, van Helsdingen, Arnold G, Vulto, Ans T, van der Ploeg, Niek P, van Til, W W M Pim, Pijnappel |
| Přispěvatelé: |
Pediatrics, Pharmacy, Hematology, Clinical Genetics |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Molecular Therapy-Methods and Clinical Development, 27, 109-130. Cell Press |
| ISSN: |
2329-0501 |
| DOI: |
10.1016/j.omtm.2022.09.010 |
| Popis: |
Pompe disease is caused by deficiency of acid α-glucosidase (GAA), resulting in glycogen accumulation in various tissues, including cardiac and skeletal muscles and the central nervous system (CNS). Enzyme replacement therapy (ERT) improves cardiac, motor, and respiratory functions but is limited by poor cellular uptake and its inability to cross the blood-brain barrier. Previously, we showed that hematopoietic stem cell (HSPC)-mediated lentiviral gene therapy (LVGT) with codon-optimized GAA (LV-GAAco) caused glycogen reduction in heart, skeletal muscles, and partially in the brain at high vector copy number (VCN). Here, we fused insulin-like growth factor 2 (IGF2) to a codon-optimized version of GAA (LV-IGF2.GAAco) to improve cellular uptake by the cation-independent mannose 6-phosphate/IGF2 (CI-M6P/IGF2) receptor. In contrast to LV-GAAco, LV-IGF2.GAAco was able to completely normalize glycogen levels, pathology, and impaired autophagy at a clinically relevant VCN of 3 in heart and skeletal muscles. LV-IGF2.GAAco was particularly effective in treating the CNS, as normalization of glycogen levels and neuroinflammation was achieved at a VCN between 0.5 and 3, doses at which LV-GAAco was largely ineffective. These results identify IGF2.GAA as a candidate transgene for future clinical development of HSPC-LVGT for Pompe disease. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
